Olumiant and Xeljanz XR Will Be the Latest Rheumatoid Arthritis Meds

Olumiant (baricitinib) and Xeljanz XR (tofacitinib) will be new once-daily oral meds for rheumatoid arthritis (RA).

Olumiant (oh-LOO-mee-ant) is the second "Janus kinase (JAK) inhibitor" for RA on the market after Xeljanz.

And once-daily Xeljanz XR may simplify dosing over twice-daily Xeljanz.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 200+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote